While CEO and COO open-market buys are strong signals, their absence isn't fatal. In Fiserv's case, recent buys from the new CFO, Chief Legal Officer, and a director with a history of successful insider trades provide critical, albeit more nuanced, confirmation of a turnaround from key oversight roles.

In biotech, CEO insider buys are common and not very predictive. The real signal comes from the rest of the management team, especially the CFO. CFOs are typically more bearish and financially disciplined, so their decision to buy company stock is a particularly strong vote of confidence.

A CFO's large personal investment, despite a significant subsequent stock price decline, indicates strong belief in a turnaround. Newell's strategy of cutting unprofitable product lines to boost profitability is being misread by the market as just falling revenue, creating a potential value opportunity.

In a powerful signal of internal optimism, Anthropic's employee stock tender offer failed to reach its full allocation. Mirroring a similar trend at OpenAI, employees are holding onto their shares—even those valued at a $380B valuation—reflecting a strong belief that the company's value will skyrocket leading up to an IPO.

The 2024 SaaS sell-off was driven by sell-side analysts setting unrealistically high growth forecasts for large incumbents. When companies inevitably decelerated, analysts lowered numbers, causing a sell-off. The cycle will reverse as companies beat these lowered expectations.

Insider buying in biotech isn't just a short-term trading signal around an event. The quantitative analysis shows its predictive power lasts for months after the transaction. This implies insiders are buying based on a durable, fundamental belief in the company's science and trajectory, not just upcoming news.

The recent $300B SaaS stock sell-off wasn't driven by current performance. Investors are repricing stocks based on deep uncertainty about whether legacy software companies or AI-native firms will capture the value of automating human labor in the next 3-5 years.

Insiders and CEOs are generally good at timing capital allocation, issuing shares when prices are high and buying back when low. The current lack of equity issuance from high-flying tech companies suggests their leadership doesn't view their stock as overvalued, despite having clear reasons to raise capital.

A tender offer, where a company buys a large block of its stock in a set price range, signals higher conviction than a typical buyback program. It forces management to put a stake in the ground, indicating they believe the shares are significantly undervalued at a specific price.